Express Mail Label No.: EV463103815US

Date of Deposit: January 6, 2006 Attorney Docket No.: 21402-661 (CURA 961)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Corvalan et al.

ERIAL NUMBER:

10/041,860

EXAMINER:

Phuong N. Huynh

FILING DATE:

January 7, 2002

ART UNIT:

1644

For:

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Mail Stop RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed concurrently with the filing of this RCE application. Accordingly, no fee or certification is believed required. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A20 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS:

Corvalan et al.

U.S.S.N.:

10/041,860

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-661.

Respectfully submitted,

Wor R. Elrifi, Reg. No. 39,529

Attorney for Applicant c/o MINTZ, LEVIN Tel: (617) 542-6000 Fax: (617) 542-2241 Customer No.: 55111

Date: January 6, 2006

TRA 2109493v.1

Express Mail Label: EV 463103815 US Date of Deposit: January 6, 2006

Page 1 of 4 Attorney Docket No.: 21402-661 (CURA 961)

Please type a plus sign (+) in this box +

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/041,860
Filing Date	January 7, 2002
First Named Inventor	Corvalan
Group Art Unit	1644
Examiner Name	Phuong N. Huynh
Attorney Docket Number	21402-661 (CURA 961)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	4,683,195	07/28/87	Mullis et al.	435	6	
	*A2	4,683,202	07/28/87	Mullis	435	91	
	*A3	4,816,397	03/28/89	Boss et al.	435	68	
	*A4	5,151,510	09/29/92	Stec et al.	536	27	
	*A5	5,194,594	03/16/93	Khawli et al.	530	391.5	
	*A6	5,733,743	03/31/98	Johnson et al.	435	69.1	
	*A7	5,916,771	06/29/99	Hori et al.	435	69.6	
	*A8	6,207,418 B1	03/27/01	Hori et al.	435	69.6	
	*A9	6,432,673 B1	08/13/02	Gao et al.	435	69.1	
· · · · · · · · · · · · · · · · · · ·	*A10	6,468,543 B1	10/22/02	Gilbertson et al.	424	198.1	
***	*A11	6,495,668 B1	12/17/02	Gilbert et al.	530	399	
	*A12	6,528,050 B1	03/04/03	Gao et al.	424	85.1	
	*A13	6,630,142 B2	10/07/03	Hart et al.	424	145.1	
	*A14	6,706,687 B1	03/16/04	Eriksson et al.	514	12	
	*A15	6,814,965 B2	11/09/04	Gao et al.	424	133.1	
	*A16	6,827,938 B2	21/07/04	Hart et al.	424	198.1	
	*A17	6,866,991 B2	03/15/05	Gilbertson et al.	435	1.1	
	*A18	6,887,982 B1	05/03/05	Gao et al.	530	387.9	
	*A19	6,893,637 B1	05/17/05	Gilbertson	424	133.1	
	*A20	6,962,802 B2	11/08/05	Gilbert et al.	435	69.4	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.			Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	wo	94/29444	THE GOV. OF THE U.S.A. represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES	12/22/94		
	B2	wo	97/38137	MERCATOR GENETICS, INC.	10/16/97		
	В3	wo	01/25433 A2	GENENTECH, INC.; CURAGEN CORPORATION	04/12/01		

Page 2 of 4 Attorney Docket No.: 21402-661 (CURA 961)

Express Mail Label: EV 463103815 US Date of Deposit: January 6, 2006

	T =.	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
xam nitials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Alon et al. Nat. Med., 1(10):1024-1028 (1995)
-	C2	Athanassiades et al. Placenta, 19(7): 465-473 (1998)
	C3	Baldrick, Regul. Toxicol. Pharmacol., 32(2):210-218 (2000)
	C4	Bellamy et al. Cancer Res., 59(3):728-733 (1999)
-	C5	Blake et al. BioConjugate Chem., Abstract only, 3:510-513 (1992)
	C6	Bowie et al. Science, Abstract only, 253:164-170 (1991)
	C7	Carmeliet et al. Cell, 98(2):147-157 (1999)
	C8	Charman, J. Pharm. Sci., 89(8):967-978 (2000)
	C9	Chen et al. Hum. Gene Ther., Abstract only, 5(5):595-601 (1994)
	C10	Chiswell et al. Trends Biotechnol., Abstract only, 10(3):80-84 (1992)
	C11	Chothia et al. J. Mol. Biol., Abstract only, 196(4):901-917 (1987)
	C12	Chothia et al. Nature, 342:878-883 (1989)
	C13	Crossen et al. Cancer Genet. Cytogenet., 112:144-148 (1999)
	C14	Cwirla et al. Proc. Natl. Acad. Sci. USA, 87:6378-6382 (1990)
	C15	Deo et al. Immunol. Today, 18:127-135 (1997)
	C16	Evans et al. J. Med. Chem., Abstract only, 30(7):1229-1239 (1987).
	C17	Fanger et al. Immunomethods., Abstract only, 4(1):72-81 (1994)
	C18	Ferrara, Curr. Top Microbiol. Immunol., 237:1-30 (1999)
	C19	Ferti-Passantonopoulou et al. Cancer Genet. Cytogenet., Abstract only, 51(2):183-188 (1991)
	C20	Gerber et al. J. Biol. Chem., 273(46):30336-30343 (1998)
	C21	Gorman et al. Proc. Natl. Acad. Sci. USA, 79:6777-6781 (1982)
	C22	Green et al. J. Exp. Med., 188(3):483-495 (1998)
	C23	Green et al. Nature Genetics, 7:13-21 (1994)
	C24	Grosschedl et al. Cell, Abstract only, 41(3):885-897 (1985)
	C25	Hanes et al. Proc. Natl. Acad. Sci. USA, 94:4937-4942 (1997)
	C26	Hoogenboom et al. Immunol. Rev., Abstract only,130:41-68 (1992)
	C27	Houghten et al. Biotechniques, 13(3):412-421 (1992)
	C28	Houghten Proc. Natl. Acad. Sci. USA, 82:5131-5135 (1985)
	C29	Ike et al. Nucl. Acid Res., 11(2):477-488 (1983)
	C30	Itakura et al. Annu. Rev. Biochem., Abstract only,53:323-356 (1984)
	C31	Katoh et al. J. Gastroenterol., 31(1):137-139 (1996)
	C32	Kessler et al. Science, 271:360-362 (1996)
	C33	Kostelny et al. J. Immunol., 148:1547-1553 (1992)
	C34	Kurahashi et al. Hum. Mol. Genet., 9(11):1665-1670 (2000)
	C35	LaPlanche et al. Nucl. Acids Res., 14(22):9081-9093 (1986)
	C36	LaRochelle et al. Nat. Cell Biol., 3:517-521 (2001)
	C37	Li et al. Cell Res., 9:11-25 (1999)

Express Mail Label: EV 463103815 US Date of Deposit: January 6, 2006

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		
	C38	Liu et al. Proc. Natl. Acad. Sci. USA, 84:3439-3443 (1987)		
	C39	Liu et al. J. Immunol., Abstract only,139(10):3521-3526 (1987)		
	C40	Marasco, Gene Ther., Abstract only, 4(1):11-15 (1997)		
	C41	Masood et al., Proc. Natl. Acad. Sci. USA, 94(3): 979-984 (1997)		
	C42	Mendez et al. Nat. Genet., 15:146-156 (1997)		
	C43	Michaux et al. Genes, Chromosomes & Cancer, 29:40-47 (2000)		
	C44	Narang, Tetrahedron, Abstract only, 39(1):3-22 (1983)		
	C45	Needleman et al. J. Mol. Biol., 48:443-453 (1970)		
	C46	Okayama et al. Mol. Cell. Biol., 3(2):280-289 (1983)		
	C47	Parmley et al. Gene, Abstract only, 73(2):305-318 (1988)		
	C48	Pearson et al. Proc. Natl. Acad. Sci. USA, 85:2444-2448 (1988)		
	C49	Pinilla et al. Biotechniques, Abstract only, 13(6):901-905 (1992)		
	C50	Pivnick et al. J. Med. Genet., Abstract only, 33(9):772-778 (1996)		
<u> </u>	C51	Powell et al. PDA J. Pharm. Sci. Technol., Abstract only, 52(5):238-311 (1998)		
	C52	Risau et al., Annu. Rev. Cell Dev. Biol., 11: 73-91 (1995)		
	C53	Risau, FASEB J., 9(10): 926-933 (1995)		
	C54	Rizo et al. Annu. Rev. Biochem., Abstract only, 61:387-418 (1992)		
	C55	Russell et al. Nucl. Acids Res., 21(5):1081-1085 (1993)		
	C56	Scott, Trends Biochem. Sci., Abstract only, 17(7):241-245 (1992)		
	C57	Shen et al. J. Surg. Oncol., Abstract only, 74(2):100-107 (2000)		
	C58	Smith et al. Adv. Appl. Math., Abstract only, 2(4):482-489 (1981)		
	C59	Songsivilai et al. Clin. Exp. Immunol., Abstract only, 79(3):315-321 (1990)		
	C60	Speirs et al. Br. J. Cancer, 80(5/6): 898-903(1999)		
* -	C61	Stec et al. J. Am. Chem. Soc., Abstract only, 106:6077-6079 (1984)		
	C62	Stein et al. Nucl. Acids Res., 16:3209-3221 (1988)		
	C63	Tarkkanen et al. Genes, Chromosomes & Cancer, 25:323-331 (1999)		
	C64	Thornton et at. Nature, 354:105-106 (1991)		
	C65	Traunecker et al. Int. J. Cancer (Suppl.), Abstract only,7:51-52 (1992)		
	C66	Uhlmann et al. Chem. Rev., Abstract only, 90(4):543 (1990)		
	C67	Valerius et al. <i>Blood</i> , 90(11):4485-4492 (1997)		
	C68	Veber et al. Trends in Neurosci., Abstract only, 8:392-396 (1985)		
	C69	Vitetta et al. Immunol. Today, Abstract only,14(6):252-259 (1993)		
	C70	Wang, Int. J. Pharm., 203(1-2):1-60 (2000)		
	C71	Warren et al. J. Clin. Invest., 95:1789-1797 (1995)		
	C72	Winter et al. Immunol. Today, Abstract only, 14(6):243-246 (1993)		
	C73	Wozney et al. Science, 242:1528-1534 (1988)		
	C74	Wright et al. Crit. Rev. Immunol., Abstract only, 12(3-4):125-168 (1992)		

Express Mail Label: EV 463103815 US Date of Deposit: January 6, 2006

Page 4 of 4 Attorney Docket No.: 21402-661 (CURA 961)

<u> </u>	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
	C75	Yoshikawa et al. Cancer, 56:1682-1687 (1985)			
-	C76	Yuan et al. Proc. Natl. Acad. Sci. USA, 93:14765-14770 (1996)			
	C77	Zon et al. Anti-Cancer Drug Des., Abstract only,6(6):539-568 (1991)			

^{*} By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A20 are not submitted.

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2109188v.1